Assessment of Thrombogenicity in Acute Coronary Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-10-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess platelet dependent thrombogenicity in patients after acute coronary syndrome using an ex vivo arterial injury model.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Persistent Platelet Reactivity in Acute Coronary Syndrome

NCT02038309

Acute Coronary Syndrome

COMPLETED

Multimarker Evaluation of Platelet Activity and Agregation in ACS

NCT06177587

Acute Coronary Syndrome

COMPLETED

Pilot Study on Shear-induced Platelet Aggregation in Acute Coronary Syndromes

NCT00299143

Angina, Unstable

COMPLETED

Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge

NCT01171404

ACS Acute Coronary Syndrome Myocardial Infarction +2 more

COMPLETED

Antiplatelet Response, Interval Variability & Events in Percutaneous Coronary Intervention (ARIVE-PCI) Registry

NCT01278043

Coronary Artery Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Abnormal platelet activity seen in patients with Type2 Diabetes Mellitus (T2DM) may be an important contributor to their enhanced cardiovascular risk and higher rates of cardiovascular events following acute coronary syndrome, despite dual antiplatelet therapy with aspirin and clopidogrel. We have earlier demonstrated high thrombogenicity in individuals with T2DM and CAD in the absence of acute ischaemic events, despite therapeutic doses of aspirin.We hypothesise that patients with T2DM will have increased thrombogenicity after acute coronary syndrome despite optimal secondary prevention medication.Measuring ex vivo thrombus area using an arterial injury model simulates plaque rupture and reflects the summative effect of all haemostatic abnormalities. The thrombus area of patients with ACS and T2DM will be compared to the controls without T2DM.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus Acute Coronary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Type 2 diabetes mellitus

We aim to determine the effects of dual antiplatelet therapy with aspirin 75mg once a day and clopidogrel 75mg once a day on platelet dependent thrombogenicity in patients with type 2 diabetes mellitus and acute coronary syndrome. Eighty patients (40 with type 2 diabetes and 40 without) have been studied one week after Non ST-elevation acute coronary syndrome. All patients were on secondary prevention therapy as recommended by international guidelines.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acute coronary syndrome (WHO criteria) with raised cardiac troponin T
* Aged 18-80 years
* Stable Acute coronary syndrome
* On aspirin and clopidogrel
* Willing to participate in the study

Exclusion Criteria

* Smoking (current smokers or smokers who quit in the last 6 months preceding recruitment)
* Malignancy (any suspected or proven)
* Haematological disorders (bleeding disorders)
* Pre-menopausal women
* Use of corticosteroids/other antithrombotic agents (warfarin)
* Chronic liver disease
* Unable to consent

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No